This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cancrum oris

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Noma (cancrum oris)

  • is a severely debilitating orofacial disease
    • is a gangrenous infection that causes rapid, widespread orofacial destruction
  • most frequently affects children between 2 and 5 years of age who live in low-income settings in Africa and Asia (2)
    • the World Health Organization (WHO) estimates that 140,000 new cases of noma occur annually (2)
      • affects malnourished children and mainly observed in tropical countries, particularly sub-Saharan Africa (3)
      • was once frequently reported in Europe and North America, although as living conditions improved in these settings, noma has been eradicated (besides a few sporadic cases in immunocompromised individuals)
        • leukaemic patients:
          • often a terminal complicaton of the disease
          • associated with the use of anti-inflammatory and immunosuppressive drugs
    • a mortality rate of approximately 85% and a burden of disease calculated to be a loss of 1-10 million disability-adjusted life year (3)
  • cause of noma is unknown, and noma is not contagious (1)
    • main risk factors for noma include chronic malnutrition, a lack of access to healthcare (specifically immunizations), and comorbidities such as measles and human immunodeficiency virus (HIV)
      • measles:
        • especially in the malnourished, typically in children in tropical Africa
        • cranium oris develops from an acute, ulcerative gingivitis
  • pathogenesis is a fast-spreading, noncontagious gangrenous infection occurring in the face, often preceded by acute necrotizing gingivitis, and stomatitis (3)
    • rare microbiological studies suggest an opportunistic infection caused by an imbalance in normal intraoral microorganisms
  • WHO classifies noma into stages: Stage 0: simple gingivitis, Stage 1: acute necrotizing gingivitis, Stage 2: oedema, Stage 3: gangrene, Stage 4: scarring, and Stage 5: sequelae
  • reported mortality rate for untreated patients is 90% within weeks after the onset of first symptoms (1)
    • treatment in the early acute stages with antibiotics, wound debridement, and nutritional support greatly reduces mortality and morbidity
    • late treatment consists of surgical rehabilitation, which is often complex (3)
  • survivors of the acute stages of noma face a lifetime of functional challenges such as difficulty eating and speaking

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.